229 related articles for article (PubMed ID: 36439629)
21. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N
Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481
[TBL] [Abstract][Full Text] [Related]
22. Irisin alleviates obesity-induced bone loss by inhibiting interleukin 6 expression via TLR4/MyD88/NF-κB axis in adipocytes.
Zhang Y; He X; Wang K; Xue Y; Hu S; Jin Y; Zhu G; Shi Q; Rui Y
J Adv Res; 2024 Apr; ():. PubMed ID: 38626873
[TBL] [Abstract][Full Text] [Related]
23. CircRNA AFF4 induced by KDM1A promotes osteogenic differentiation through FNDC5/Irisin pathway.
Liu A; Chen Y; Zhong D; Wang C; Yu M; Liu C; Yang Z; Chen W; Yin K
Mol Med; 2022 Nov; 28(1):134. PubMed ID: 36401176
[TBL] [Abstract][Full Text] [Related]
24. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse.
Cardinal M; Chretien A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Manicourt DH; Behets C
Front Genet; 2021; 12():705505. PubMed ID: 34447412
[TBL] [Abstract][Full Text] [Related]
25. [Study on the gelatin methacryloyl composite scaffold with exogenous transforming growth factor β
Liu X; Wang Z; Xu C; Guan J; Wei B; Liu Y
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2021 Jul; 35(7):904-912. PubMed ID: 34308601
[TBL] [Abstract][Full Text] [Related]
26. Antagonism Between PEDF and TGF-β Contributes to Type VI Osteogenesis Imperfecta Bone and Vascular Pathogenesis.
Kang H; Aryal Ac S; Barnes AM; Martin A; David V; Crawford SE; Marini JC
J Bone Miner Res; 2022 May; 37(5):925-937. PubMed ID: 35258129
[TBL] [Abstract][Full Text] [Related]
27. Biomechanical, Microstructural and Material Properties of Tendon and Bone in the Young Oim Mice Model of Osteogenesis Imperfecta.
Chretien A; Couchot M; Mabilleau G; Behets C
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077325
[TBL] [Abstract][Full Text] [Related]
28. Whole-Body Metabolism and the Musculoskeletal Impacts of Targeting Activin A and Myostatin in Severe Osteogenesis Imperfecta.
Omosule CL; Joseph D; Weiler B; Gremminger VL; Silvey S; Lafaver BN; Jeong Y; Kleiner S; Phillips CL
JBMR Plus; 2023 Jul; 7(7):e10753. PubMed ID: 37457877
[TBL] [Abstract][Full Text] [Related]
29. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
McCarthy EA; Raggio CL; Hossack MD; Miller EA; Jain S; Boskey AL; Camacho NP
Pediatr Res; 2002 Nov; 52(5):660-70. PubMed ID: 12409511
[TBL] [Abstract][Full Text] [Related]
30. Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine.
Matthews BG; Roeder E; Wang X; Aguila HL; Lee SK; Grcevic D; Kalajzic I
Bone; 2017 Oct; 103():1-11. PubMed ID: 28600151
[TBL] [Abstract][Full Text] [Related]
31. Craniofacial dysmorphism of osteogenesis imperfecta mouse and effect of cathepsin K knockout: Preliminary craniometry observations.
Fosséprez J; Roels T; Manicourt D; Behets C
Morphologie; 2024 May; 108(362):100785. PubMed ID: 38788496
[TBL] [Abstract][Full Text] [Related]
32. Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.
Jeong Y; Daghlas SA; Kahveci AS; Salamango D; Gentry BA; Brown M; Rector RS; Pearsall RS; Phillips CL
Muscle Nerve; 2018 Feb; 57(2):294-304. PubMed ID: 28555931
[TBL] [Abstract][Full Text] [Related]
33. Distinct type I collagen alterations cause intrinsic lung and respiratory defects of variable severity in mouse models of osteogenesis imperfecta.
Dimori M; Fett J; Leikin S; Otsuru S; Thostenson JD; Carroll JL; Morello R
J Physiol; 2023 Jan; 601(2):355-379. PubMed ID: 36285717
[TBL] [Abstract][Full Text] [Related]
34. DNA methyltransferases inhibitor azacitidine improves the skeletal phenotype of mild osteogenesis imperfecta by reversing the impaired osteogenesis and excessive osteoclastogenesis.
Shao C; Liu Y; Zhao Y; Jing Y; Li J; Lv Z; Fu T; Wang Z; Li G
Bone; 2023 May; 170():116706. PubMed ID: 36822490
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Misof BM; Roschger P; Baldini T; Raggio CL; Zraick V; Root L; Boskey AL; Klaushofer K; Fratzl P; Camacho NP
Bone; 2005 Jan; 36(1):150-8. PubMed ID: 15664013
[TBL] [Abstract][Full Text] [Related]
36. TGF-β inhibits osteogenesis by upregulating the expression of ubiquitin ligase SMURF1 via MAPK-ERK signaling.
Sun X; Xie Z; Ma Y; Pan X; Wang J; Chen Z; Shi P
J Cell Physiol; 2018 Jan; 233(1):596-606. PubMed ID: 28322449
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse bone.
Vanleene M; Shefelbine SJ
Bone; 2013 Apr; 53(2):507-14. PubMed ID: 23352925
[TBL] [Abstract][Full Text] [Related]
38. Experimental study of the synergistic effect and network regulation mechanisms of an applied combination of BMP-2, VEGF, and TGF-β1 on osteogenic differentiation.
Wang Z; Sun J; Li Y; Chen C; Xu Y; Zang X; Li L; Meng K
J Cell Biochem; 2020 Mar; 121(3):2394-2405. PubMed ID: 31646676
[TBL] [Abstract][Full Text] [Related]
39. Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
Jeong Y; Daghlas SA; Xie Y; Hulbert MA; Pfeiffer FM; Dallas MR; Omosule CL; Pearsall RS; Dallas SL; Phillips CL
J Bone Miner Res; 2018 Oct; 33(10):1760-1772. PubMed ID: 29813187
[TBL] [Abstract][Full Text] [Related]
40. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.
Delos D; Yang X; Ricciardi BF; Myers ER; Bostrom MP; Camacho NP
J Orthop Res; 2008 Feb; 26(2):153-64. PubMed ID: 17729310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
